Suppr超能文献

MK-0524 对前列腺素 DP1 受体的反向激动剂和药理学伴侣特性。

Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.

机构信息

Département de Médecine, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

出版信息

PLoS One. 2013 Jun 10;8(6):e65767. doi: 10.1371/journal.pone.0065767. Print 2013.

Abstract

Prostaglandin D₂ (PGD₂) acts through two G protein-coupled receptors (GPCRs), the prostanoid DP receptor and CRTH2 also known as DP1 and DP2, respectively. Several previously characterized GPCR antagonists are now classified as inverse agonists and a number of GPCR ligands are known to display pharmacochaperone activity towards a given receptor. Here, we demonstrate that a DP1 specific antagonist, MK-0524 (also known as laropiprant), decreased basal levels of intracellular cAMP produced by DP1, a Gα(s)-coupled receptor, in HEK293 cells. This reduction in cAMP levels was not altered by pertussis toxin treatment, indicating that MK-0524 did not induce coupling of DP1 to Gα(i/o) proteins and that this ligand is a DP1 inverse agonist. Basal ERK1/2 activation by DP1 was not modulated by MK-0524. Interestingly, treatment of HEK293 cells expressing Flag-tagged DP1 with MK-0524 promoted DP1 cell surface expression time-dependently to reach a maximum increase of 50% compared to control after 24 h. In contrast, PGD₂ induced the internalization of 75% of cell surface DP1 after the same time of stimulation. The increase in DP1 cell surface targeting by MK-0524 was inhibited by Brefeldin A, an inhibitor of transport from the endoplasmic reticulum-Golgi to the plasma membrane. Confocal microscopy confirmed that a large population of DP1 remained trapped intracellularly and co-localized with calnexin, an endoplasmic reticulum marker. Redistribution of DP1 from intracellular compartments to the plasma membrane was observed following treatment with MK-0524 for 24 h. Furthermore, MK-0524 promoted the interaction between DP1 and the ANKRD13C protein, which we showed previously to display chaperone-like effects towards the receptor. We thus report that MK-0524 is an inverse agonist and a pharmacochaperone of DP1. Our findings may have important implications during therapeutic treatments with MK-0524 and for the development of new molecules targeting DP1.

摘要

前列腺素 D2(PGD2)通过两种 G 蛋白偶联受体(GPCR)发挥作用,即前列腺素 DP 受体和 CRTH2,也分别称为 DP1 和 DP2。目前,几种已被表征的 GPCR 拮抗剂被归类为反向激动剂,并且已知许多 GPCR 配体对特定受体具有药理伴侣活性。在这里,我们证明 DP1 特异性拮抗剂 MK-0524(也称为拉罗匹坦)降低了 DP1(一种 Gα(s)偶联受体)在 HEK293 细胞中产生的细胞内 cAMP 的基础水平。这种 cAMP 水平的降低不受百日咳毒素处理的影响,表明 MK-0524 不会诱导 DP1 与 Gα(i/o)蛋白偶联,并且该配体是 DP1 反向激动剂。DP1 对基础 ERK1/2 的激活不受 MK-0524 调节。有趣的是,用 MK-0524 处理表达 Flag 标记的 DP1 的 HEK293 细胞会随时间依赖性地促进 DP1 细胞表面表达,与对照相比,24 小时后最大增加 50%。相比之下,PGD2 在相同刺激时间后诱导 75%的细胞表面 DP1 内化。MK-0524 对 DP1 细胞表面靶向的增加被布雷非德菌素 A 抑制,布雷非德菌素 A 是一种从内质网-高尔基体到质膜的运输抑制剂。共聚焦显微镜证实,大部分 DP1 仍被困在内质网中,并与 calnexin(内质网标志物)共定位。在用 MK-0524 处理 24 小时后,观察到 DP1 从细胞内隔室重新分布到质膜。此外,MK-0524 促进了 DP1 与 ANKRD13C 蛋白的相互作用,我们之前表明该蛋白对受体具有伴侣样作用。因此,我们报告 MK-0524 是 DP1 的反向激动剂和药理伴侣。我们的发现可能在 MK-0524 治疗期间以及针对 DP1 的新分子的开发中具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/961e/3677937/66c78e32ae81/pone.0065767.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验